Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters










Publication year range
2.
Nat Commun ; 6: 8501, 2015 Oct 07.
Article in English | MEDLINE | ID: mdl-26442967

ABSTRACT

The tumour suppressor PTEN, which antagonizes PI3K signalling, is frequently inactivated in haematologic malignancies. In mice, deletion of PTEN in haematopoietic stem cells (HSCs) causes perturbed haematopoiesis, myeloproliferative neoplasia (MPN) and leukaemia. Although the roles of the PI3K isoforms have been studied in PTEN-deficient tumours, their individual roles in PTEN-deficient HSCs are unknown. Here we show that when we delete PTEN in HSCs using the Mx1-Cre system, p110ß ablation prevents MPN, improves HSC function and suppresses leukaemia initiation. Pharmacologic inhibition of p110ß in PTEN-deficient mice recapitulates these genetic findings, but suggests involvement of both Akt-dependent and -independent pathways. Further investigation reveals that a p110ß-Rac signalling loop plays a critical role in PTEN-deficient HSCs. Together, these data suggest that myeloid neoplasia driven by PTEN loss is dependent on p110ß via p110ß-Rac-positive-feedback loop, and that disruption of this loop may offer a new and effective therapeutic strategy for PTEN-deficient leukaemia.


Subject(s)
Class I Phosphatidylinositol 3-Kinases/genetics , Hematopoiesis/genetics , Hematopoietic Stem Cells/metabolism , Leukemia/genetics , Myeloproliferative Disorders/genetics , PTEN Phosphohydrolase/genetics , Animals , Blotting, Western , Bone Marrow/metabolism , Carcinogenesis/genetics , Chemotaxis , Flow Cytometry , Immunohistochemistry , Mice , rac GTP-Binding Proteins
3.
EMBO J ; 34(15): 2042-58, 2015 Aug 04.
Article in English | MEDLINE | ID: mdl-26139534

ABSTRACT

T cells infiltrating neoplasms express surface molecules typical of chronically virus-stimulated T cells, often termed "exhausted" T cells. We compared the transcriptome of "exhausted" CD8 T cells infiltrating autochthonous melanomas to those of naïve and acutely stimulated CD8 T cells. Despite strong similarities between transcriptional signatures of tumor- and virus-induced exhausted CD8 T cells, notable differences appeared. Among transcriptional regulators, Nr4a2 and Maf were highly overexpressed in tumor-exhausted T cells and significantly upregulated in CD8 T cells from human melanoma metastases. Transduction of murine tumor-specific CD8 T cells to express Maf partially reproduced the transcriptional program associated with tumor-induced exhaustion. Upon adoptive transfer, the transduced cells showed normal homeostasis but failed to accumulate in tumor-bearing hosts and developed defective anti-tumor effector responses. We further identified TGFß and IL-6 as main inducers of Maf expression in CD8 T cells and showed that Maf-deleted tumor-specific CD8 T cells were much more potent to restrain tumor growth in vivo. Therefore, the melanoma microenvironment contributes to skewing of CD8 T cell differentiation programs, in part by TGFß/IL-6-mediated induction of Maf.


Subject(s)
CD8-Positive T-Lymphocytes/cytology , Cell Differentiation/immunology , Melanoma/metabolism , Proto-Oncogene Proteins c-maf/metabolism , Tumor Microenvironment/physiology , Animals , CD8-Positive T-Lymphocytes/metabolism , DNA Primers/genetics , Flow Cytometry , Gene Expression Profiling , Homeodomain Proteins/genetics , Interleukin-6/metabolism , Luciferases , Mice , Mice, Transgenic , Proto-Oncogene Proteins c-maf/genetics , Real-Time Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction , Transforming Growth Factor beta/metabolism
4.
Nat Cell Biol ; 16(11): 1080-91, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25344755

ABSTRACT

Cyclin C was cloned as a growth-promoting G1 cyclin, and was also shown to regulate gene transcription. Here we report that in vivo cyclin C acts as a haploinsufficient tumour suppressor, by controlling Notch1 oncogene levels. Cyclin C activates an 'orphan' CDK19 kinase, as well as CDK8 and CDK3. These cyclin-C-CDK complexes phosphorylate the Notch1 intracellular domain (ICN1) and promote ICN1 degradation. Genetic ablation of cyclin C blocks ICN1 phosphorylation in vivo, thereby elevating ICN1 levels in cyclin-C-knockout mice. Cyclin C ablation or heterozygosity collaborates with other oncogenic lesions and accelerates development of T-cell acute lymphoblastic leukaemia (T-ALL). Furthermore, the cyclin C encoding gene CCNC is heterozygously deleted in a significant fraction of human T-ALLs, and these tumours express reduced cyclin C levels. We also describe point mutations in human T-ALL that render cyclin-C-CDK unable to phosphorylate ICN1. Hence, tumour cells may develop different strategies to evade inhibition by cyclin C.


Subject(s)
Cyclin C/metabolism , Cyclin-Dependent Kinases/metabolism , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/metabolism , Receptor, Notch1/metabolism , Animals , Cells, Cultured , Cyclin-Dependent Kinase 3/metabolism , Cyclin-Dependent Kinase 8/metabolism , Cyclin-Dependent Kinases/genetics , Humans , Mice , Mice, Knockout , Mice, Transgenic , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/genetics
5.
Elife ; 3: e01763, 2014 May 20.
Article in English | MEDLINE | ID: mdl-24844244

ABSTRACT

Despite marked advances in breast cancer therapy, basal-like breast cancer (BBC), an aggressive subtype of breast cancer usually lacking estrogen and progesterone receptors, remains difficult to treat. In this study, we report the identification of MELK as a novel oncogenic kinase from an in vivo tumorigenesis screen using a kinome-wide open reading frames (ORFs) library. Analysis of clinical data reveals a high level of MELK overexpression in BBC, a feature that is largely dependent on FoxM1, a master mitotic transcription factor that is also found to be highly overexpressed in BBC. Ablation of MELK selectively impairs proliferation of basal-like, but not luminal breast cancer cells both in vitro and in vivo. Mechanistically, depletion of MELK in BBC cells induces caspase-dependent cell death, preceded by defective mitosis. Finally, we find that Melk is not required for mouse development and physiology. Together, these data indicate that MELK is a normally non-essential kinase, but is critical for BBC and thus represents a promising selective therapeutic target for the most aggressive subtype of breast cancer.DOI: http://dx.doi.org/10.7554/eLife.01763.001.


Subject(s)
Breast Neoplasms/pathology , Cell Proliferation , Epithelial Cells/physiology , Mitosis , Protein Serine-Threonine Kinases/metabolism , Animals , Disease Models, Animal , Female , Forkhead Box Protein M1 , Forkhead Transcription Factors/metabolism , Gene Expression Profiling , Gene Knockout Techniques , Humans , Mice , Stem Cells , Transplantation, Heterologous
6.
J Clin Invest ; 123(3): 1044-56, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23391724

ABSTRACT

Anti-self/tumor T cell function can be improved by increasing TCR-peptide MHC (pMHC) affinity within physiological limits, but paradoxically further increases (K(d) < 1 µM) lead to drastic functional declines. Using human CD8(+) T cells engineered with TCRs of incremental affinity for the tumor antigen HLA-A2/NY-ESO-1, we investigated the molecular mechanisms underlying this high-affinity-associated loss of function. As compared with cells expressing TCR affinities generating optimal function (K(d) = 5 to 1 µM), those with supraphysiological affinity (K(d) = 1 µM to 15 nM) showed impaired gene expression, signaling, and surface expression of activatory/costimulatory receptors. Preferential expression of the inhibitory receptor programmed cell death-1 (PD-1) was limited to T cells with the highest TCR affinity, correlating with full functional recovery upon PD-1 ligand 1 (PD-L1) blockade. In contrast, upregulation of the Src homology 2 domain-containing phosphatase 1 (SHP-1/PTPN6) was broad, with gradually enhanced expression in CD8(+) T cells with increasing TCR affinities. Consequently, pharmacological inhibition of SHP-1 with sodium stibogluconate augmented the function of all engineered T cells, and this correlated with the TCR affinity-dependent levels of SHP-1. These data highlight an unexpected and global role of SHP-1 in regulating CD8(+) T cell activation and responsiveness and support the development of therapies inhibiting protein tyrosine phosphatases to enhance T cell-mediated immunity.


Subject(s)
CD8-Positive T-Lymphocytes/immunology , Lymphocyte Activation , Protein Tyrosine Phosphatase, Non-Receptor Type 6/metabolism , Receptors, Antigen, T-Cell, alpha-beta/metabolism , Antigens, Neoplasm/immunology , Antimony Sodium Gluconate/pharmacology , CD8-Positive T-Lymphocytes/enzymology , CD8-Positive T-Lymphocytes/physiology , Cell Line , Down-Regulation/immunology , Extracellular Signal-Regulated MAP Kinases/metabolism , HLA-A2 Antigen/immunology , Humans , Immunotherapy, Adoptive , Membrane Proteins/immunology , MicroRNAs/genetics , MicroRNAs/metabolism , Phosphorylation , Programmed Cell Death 1 Receptor/genetics , Programmed Cell Death 1 Receptor/metabolism , Programmed Cell Death 1 Receptor/physiology , Protein Binding , Protein Processing, Post-Translational , Protein Tyrosine Phosphatase, Non-Receptor Type 6/antagonists & inhibitors , Protein Tyrosine Phosphatase, Non-Receptor Type 6/genetics , Receptors, Antigen, T-Cell, alpha-beta/genetics , Signal Transduction/immunology , Transcriptome , ZAP-70 Protein-Tyrosine Kinase/metabolism
7.
J Immunother ; 35(6): 488-501, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22735807

ABSTRACT

Phenotypic and functional cell properties are usually analyzed at the level of defined cell populations but not single cells. Yet, large differences between individual cells may have important functional consequences. It is likely that T-cell-mediated immunity depends on the polyfunctionality of individual T cells, rather than the sum of functions of responding T-cell subpopulations. We performed highly sensitive single-cell gene expression profiling, allowing the direct ex vivo characterization of individual virus-specific and tumor-specific T cells from healthy donors and melanoma patients. We have previously shown that vaccination with the natural tumor peptide Melan-A-induced T cells with superior effector functions as compared with vaccination with the analog peptide optimized for enhanced HLA-A*0201 binding. Here we found that natural peptide vaccination induced tumor-reactive CD8 T cells with frequent coexpression of both memory/homing-associated genes (CD27, IL7R, EOMES, CXCR3, and CCR5) and effector-related genes (IFNG, KLRD1, PRF1, and GZMB), comparable with protective Epstein-Barr virus-specific and cytomegalovirus-specific T cells. In contrast, memory/homing-associated and effector-associated genes were less frequently coexpressed after vaccination with the analog peptide. Remarkably, these findings reveal a previously unknown level of gene expression diversity among vaccine-specific and virus-specific T cells with the simultaneous coexpression of multiple memory/homing-related and effector-related genes by the same cell. Such broad functional gene expression signatures within antigen-specific T cells may be critical for mounting efficient responses to pathogens or tumors. In summary, direct ex vivo high-resolution molecular characterization of individual T cells provides key insights into the processes shaping the functional properties of tumor-specific and virus-specific T cells.


Subject(s)
CD8-Positive T-Lymphocytes/immunology , Epitopes , Immunologic Memory , Lymphocyte Activation , Melanoma/genetics , Cancer Vaccines/immunology , Cells, Cultured , Gene Expression Profiling , Granzymes/biosynthesis , HLA-A2 Antigen , Humans , Interferon-gamma/biosynthesis , MART-1 Antigen/immunology , Melanoma/immunology , NK Cell Lectin-Like Receptor Subfamily D/biosynthesis , Perforin , Pore Forming Cytotoxic Proteins/biosynthesis , Receptors, CCR5/biosynthesis , Receptors, CXCR3/biosynthesis , Receptors, Interleukin-7/biosynthesis , T-Box Domain Proteins/biosynthesis , Tumor Necrosis Factor Receptor Superfamily, Member 7/biosynthesis , Vaccines, Subunit/immunology
8.
Trends Immunol ; 33(7): 364-72, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22445288

ABSTRACT

Memory and effector T cells have the potential to counteract cancer progression, but often fail to control the disease, essentially because of three main stumbling blocks. First, clonal deletion leads to relatively low numbers or low-to-intermediate T cell receptor (TCR) affinity of self/tumor-specific T cells. Second, the poor innate immune stimulation by solid tumors is responsible for inefficient priming and boosting. Third, T cells are suppressed in the tumor microenvironment by inhibitory signals from other immune cells, stroma and tumor cells, which induces T cell exhaustion, as demonstrated in metastases of melanoma patients. State-of-the-art adoptive cell transfer and active immunotherapy can partially overcome the three stumbling blocks. The reversibility of T cell exhaustion and novel molecular insights provide the basis for further improvements of clinical immunotherapy.


Subject(s)
Neoplasms/immunology , T-Lymphocytes/immunology , Animals , Autoimmunity , Disease Progression , Humans , Immunotherapy , Neoplasms/pathology , Neoplasms/therapy , Signal Transduction , T-Lymphocytes/metabolism
9.
PLoS One ; 7(2): e30852, 2012.
Article in English | MEDLINE | ID: mdl-22347406

ABSTRACT

Inhibitory receptors mediate CD8 T-cell hyporesponsiveness against cancer and infectious diseases. PD-1 and CTLA-4 have been extensively studied, and blocking antibodies have already shown clinical benefit for cancer patients. Only little is known on extended co-expression of inhibitory receptors and their ligands. Here we analyzed the expression of eight inhibitory receptors by tumor-antigen specific CD8 T-cells. We found that the majority of effector T-cells simultaneously expressed four or more of the inhibitory receptors BTLA, TIM-3, LAG-3, KRLG-1, 2B4, CD160, PD-1 and CTLA-4. There were major differences depending on antigen-specificity, differentiation and anatomical localization of T-cells. On the other hand, naive T-cells were only single or double positive for BTLA and TIM-3. Extended co-expression is likely relevant for effector T-cells, as we found expression of multiple ligands in metastatic lesions of melanoma patients. Together, our data suggest that naive T-cells are primarily regulated by BTLA and TIM-3, whereas effector cells interact via larger numbers of inhibitory receptors. Blocking multiple inhibitory receptors simultaneously or sequentially may improve T-cell based therapies, but further studies are necessary to clarify the role of each receptor-ligand pair.


Subject(s)
CD8-Positive T-Lymphocytes/immunology , Cell Differentiation/immunology , Receptors, KIR/biosynthesis , T-Cell Antigen Receptor Specificity/immunology , Antibodies, Blocking/therapeutic use , Antigens, Neoplasm , CD8-Positive T-Lymphocytes/cytology , Hepatitis A Virus Cellular Receptor 2 , Humans , Immunologic Factors , Membrane Proteins/immunology , Neoplasms/immunology , Neoplasms/pathology , Receptors, Immunologic/immunology , Receptors, KIR/immunology
10.
Int J Cancer ; 130(11): 2607-17, 2012 Jun 01.
Article in English | MEDLINE | ID: mdl-21796616

ABSTRACT

T-cells specific for foreign (e.g., viral) antigens can give rise to strong protective immune responses, whereas self/tumor antigen-specific T-cells are thought to be less powerful. However, synthetic T-cell vaccines composed of Melan-A/MART-1 peptide, CpG and IFA can induce high frequencies of tumor-specific CD8 T-cells in PBMC of melanoma patients. Here we analyzed the functionality of these T-cells directly ex vivo, by multiparameter flow cytometry. The production of multiple cytokines (IFNγ, TNFα, IL-2) and upregulation of LAMP-1 (CD107a) by tumor (Melan-A/MART-1) specific T-cells was comparable to virus (EBV-BMLF1) specific CD8 T-cells. Furthermore, phosphorylation of STAT1, STAT5 and ERK1/2, and expression of CD3 zeta chain were similar in tumor- and virus-specific T-cells, demonstrating functional signaling pathways. Interestingly, high frequencies of functionally competent T-cells were induced irrespective of patient's age or gender. Finally, CD8 T-cell function correlated with disease-free survival. However, this result is preliminary since the study was a Phase I clinical trial. We conclude that human tumor-specific CD8 T-cells can reach functional competence in vivo, encouraging further development and Phase III trials assessing the clinical efficacy of robust vaccination strategies.


Subject(s)
Antigens, Neoplasm/immunology , CD8-Positive T-Lymphocytes/immunology , Vaccination , Adult , Aged , CD3 Complex/analysis , Extracellular Signal-Regulated MAP Kinases/metabolism , Female , Humans , Immunocompetence , MART-1 Antigen/immunology , Male , Middle Aged , Phosphorylation , STAT1 Transcription Factor/metabolism , STAT5 Transcription Factor/metabolism
11.
Proc Natl Acad Sci U S A ; 108(37): 15318-23, 2011 Sep 13.
Article in English | MEDLINE | ID: mdl-21876175

ABSTRACT

Immune protection from infectious diseases and cancer is mediated by individual T cells of different clonal origin. Their functions are tightly regulated but not yet fully characterized. Understanding the contribution of each T cell will improve the prediction of immune protection based on laboratory assessment of T-cell responses. Here we developed techniques for simultaneous molecular and functional assessment of single CD8 T cells directly ex vivo. We studied two groups of patients with melanoma after vaccination with two closely related tumor antigenic peptides. Vaccination induced T cells with strong memory and effector functions, as found in virtually all T cells of the first patient group, and fractions of T cells in the second group. Interestingly, high functionality was not restricted to dominant clonotypes. Rather, dominant and nondominant clonotypes acquired equal functional competence. In parallel, this was also found for EBV- and CMV-specific T cells. Thus, the nondominant clonotypes may contribute similarly to immunity as their dominant counterparts.


Subject(s)
CD8-Positive T-Lymphocytes/cytology , CD8-Positive T-Lymphocytes/immunology , Single-Cell Analysis/methods , Amino Acid Sequence , Antigens, Neoplasm/immunology , CD8-Positive T-Lymphocytes/virology , Cancer Vaccines/immunology , Cell Differentiation/immunology , Cell Proliferation , Clone Cells , Cytomegalovirus/immunology , Cytotoxicity, Immunologic , Gene Expression Profiling , Humans , Melanoma/immunology , Molecular Sequence Data , Receptors, Antigen, T-Cell/immunology , Species Specificity , Vaccination , Vaccines, Subunit/chemistry , Vaccines, Subunit/immunology
12.
J Clin Invest ; 121(6): 2350-60, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21555851

ABSTRACT

In chronic viral infections, CD8⁺ T cells become functionally deficient and display multiple molecular alterations. In contrast, only little is known of self- and tumor-specific CD8⁺ T cells from mice and humans. Here we determined molecular profiles of tumor-specific CD8⁺ T cells from melanoma patients. In peripheral blood from patients vaccinated with CpG and the melanoma antigen Melan-A/MART-1 peptide, we found functional effector T cell populations, with only small but nevertheless significant differences in T cells specific for persistent herpesviruses (EBV and CMV). In contrast, Melan-A/MART-1-specific T cells isolated from metastases from patients with melanoma expressed a large variety of genes associated with T cell exhaustion. The identified exhaustion profile revealed extended molecular alterations. Our data demonstrate a remarkable coexistence of effector cells in circulation and exhausted cells in the tumor environment. Functional T cell impairment is mediated by inhibitory receptors and further molecular pathways, which represent potential targets for cancer therapy.


Subject(s)
CD8-Positive T-Lymphocytes/pathology , CpG Islands/immunology , Gene Expression Profiling , MART-1 Antigen/immunology , Melanoma/immunology , Melanoma/secondary , T-Lymphocyte Subsets/pathology , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/metabolism , Cancer Vaccines/immunology , Cancer Vaccines/therapeutic use , Cytomegalovirus/immunology , Cytomegalovirus Infections/immunology , Epstein-Barr Virus Infections/immunology , Herpesvirus 4, Human/immunology , Humans , Lymphocytes, Tumor-Infiltrating/immunology , Melanoma/therapy , Molecular Sequence Data , Receptors, Immunologic/biosynthesis , Receptors, Immunologic/genetics , T-Cell Antigen Receptor Specificity , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/metabolism , Vaccination , Virus Latency/immunology
13.
J Transl Med ; 9: 44, 2011 Apr 20.
Article in English | MEDLINE | ID: mdl-21507256

ABSTRACT

BACKGROUND: The differentiation of CD8+ T lymphocytes following priming of naïve cells is central in the establishment of the adaptive immune response. Yet, the molecular events underlying this process are not fully understood. MicroRNAs have been recently shown to play a key role in the regulation of haematopoiesis in mouse, but their implication in peripheral lymphocyte differentiation in humans remains largely unknown. METHODS: In order to explore the potential implication of microRNAs in CD8+ T cell differentiation in humans, microRNA expression profiles were analysed using microarrays and quantitative PCR in several human CD8+ T cell subsets defining the major steps of the T cell differentiation pathway. RESULTS: We found expression of a limited set of microRNAs, including the miR-17~92 cluster. Moreover, we reveal the existence of differentiation-associated regulation of specific microRNAs. When compared to naive cells, miR-21 and miR-155 were indeed found upregulated upon differentiation to effector cells, while expression of the miR-17~92 cluster tended to concomitantly decrease. CONCLUSIONS: This study establishes for the first time in a large panel of individuals the existence of differentiation associated regulation of microRNA expression in human CD8+ T lymphocytes in vivo, which is likely to impact on specific cellular functions.


Subject(s)
CD8-Positive T-Lymphocytes/metabolism , Cell Differentiation , Gene Expression Regulation , MicroRNAs/genetics , Humans , T-Lymphocyte Subsets
14.
Cancer Res ; 69(20): 8085-93, 2009 Oct 15.
Article in English | MEDLINE | ID: mdl-19808957

ABSTRACT

We have previously shown that vaccination of HLA-A2 metastatic melanoma patients with the analogue Melan-A(26-35(A27L)) peptide emulsified in a mineral oil induces ex vivo detectable specific CD8 T cells. These are further enhanced when a TLR9 agonist is codelivered in the same vaccine formulation. Interestingly, the same peptide can be efficiently recognized by HLA-DQ6-restricted CD4 T cells. We used HLA-DQ6 multimers to assess the specific CD4 T-cell response in both healthy individuals and melanoma patients. We report that the majority of melanoma patients carry high frequencies of naturally circulating HLA-DQ6-restricted Melan-A-specific CD4 T cells, a high proportion of which express FOXP3 and proliferate poorly in response to the cognate peptide. Upon vaccination, the relative frequency of multimer+ CD4 T cells did not change significantly. In contrast, we found a marked shift to FOXP3-negative CD4 T cells, accompanied by robust CD4 T-cell proliferation upon in vitro stimulation with cognate peptide. A concomitant reduction in TCR diversity was also observed. This is the first report on direct ex vivo identification of antigen-specific FOXP3+ T cells by multimer labeling in cancer patients and on the direct assessment of the impact of peptide vaccination on immunoregulatory T cells.


Subject(s)
Antigens, Neoplasm/immunology , CD4-Positive T-Lymphocytes/immunology , Forkhead Transcription Factors/metabolism , Melanoma/immunology , Neoplasm Proteins/immunology , Peptide Fragments/immunology , Th1 Cells/immunology , Adult , Aged , Cancer Vaccines/therapeutic use , Case-Control Studies , Female , HLA-A2 Antigen/immunology , HLA-DQ Antigens/immunology , HLA-DQ Antigens/metabolism , Humans , Immunotherapy , MART-1 Antigen , Male , Melanoma/secondary , Melanoma/therapy , Middle Aged , Receptors, Antigen, T-Cell , Vaccination
15.
Org Biomol Chem ; 7(19): 3947-57, 2009 Oct 07.
Article in English | MEDLINE | ID: mdl-19763297

ABSTRACT

The development of new therapeutic agents against malaria has become urgent during the past few decades, due to an increased prevalence of drug-resistant strains of malaria-causing Plasmodium parasites. Possible targets are the hemoglobin-degrading aspartic proteases, the plasmepsins. While acyclic alpha,alpha-difluoroketone hydrates have been introduced into peptidomimetics to bind to the catalytic Asp dyad of aspartic proteases, alicyclic derivatives were unknown. This paper describes a versatile synthesis of hydrated alicyclic alpha,alpha-difluoro-cyclopentanones and -cyclohexanones, decorated with appropriate substituents to fill the S1/S3 and the "flap-open" pocket at the enzyme active sites. Their biological activity was tested against plasmepsin II and IV, revealing an IC(50) value (concentration of an inhibitor at which 50% maximum initial velocity is observed) of 7 microM for the best ligand. Reference inhibitors with a protonated secondary ammonium centre to address the catalytic dyad showed similar binding affinities. The X-ray crystal structure of a cyclic alpha,alpha-difluoroketone hydrate revealed the ability of these novel building blocks to participate in H-bonding networks. The hydration of difluoroketones was also investigated in solution. An exemplary study showed that the equilibrium constants for the hydration of alpha,alpha-difluorinated cyclohexanones are much higher than those for the corresponding cyclopentanones.


Subject(s)
Aspartic Acid Endopeptidases/antagonists & inhibitors , Fluorine/chemistry , Ketones/chemistry , Ketones/pharmacology , Malaria/enzymology , Protease Inhibitors/chemistry , Protease Inhibitors/pharmacology , Antimalarials/chemical synthesis , Antimalarials/chemistry , Antimalarials/metabolism , Antimalarials/pharmacology , Aspartic Acid Endopeptidases/chemistry , Aspartic Acid Endopeptidases/metabolism , Crystallography, X-Ray , Humans , Ketones/chemical synthesis , Ketones/metabolism , Magnetic Resonance Spectroscopy , Models, Molecular , Molecular Conformation , Protease Inhibitors/chemical synthesis , Protease Inhibitors/metabolism , Water/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...